Insider Selling: NxStage Medical President Sells 1,500 Shares of Stock (NXTM)
NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,500 shares of NxStage Medical stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $14.00, for a total value of $21,000.00. Following the completion of the sale, the president now directly owns 124,447 shares of the company’s stock, valued at approximately $1,742,258. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NxStage Medical (NASDAQ:NXTM) traded down 1.64% during mid-day trading on Friday, hitting $13.76. The stock had a trading volume of 374,718 shares. NxStage Medical has a 52 week low of $8.77 and a 52 week high of $15.65. The stock’s 50-day moving average is $13.7 and its 200-day moving average is $13.28. The company’s market cap is $847.7 million.
NxStage Medical (NASDAQ:NXTM) last released its earnings data on Thursday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.44 EPS for the current fiscal year.
A number of analysts have recently weighed in on NXTM shares. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating and one has assigned a buy rating to the company. NxStage Medical has a consensus rating of “Hold” and a consensus target price of $18.25.
NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.